Therefore, agents that are capable of targeting both GLP-1 and PYY secretion could be a safe and effective strategy in the prevention and treatment of T2D by promoting obesity and insulin resistance control and simultaneously improving functional β-cell mass. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.